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Safe handlingAbstract Introduction: The global prevalence of cancer is rising. Use of oral anticancer medica-
tions has expanded exponentially. Knowledge about these medications as well as safe handling
guidelines has not kept abreast with the rapidity these medications are applied in clinical practice.
They pose serious hazards on all personal involved in handling these medications as well as on
patients and their caregivers. We addressed the gaps in knowledge and safe handling of oral anti-
cancer agents among pharmacists in institutional based cancer care. Materials and Methods: We
used a 41 item questionnaire to explore three domains, pharmacists’ knowledge, safe handling prac-
tice and conﬁdence and self-improving strategies towards these agents among pharmacists in mul-
ticentre specialized cancer care. Results: Participants included 120 pharmacists dedicated to handle
and dispense oral anticancer agents. About 20% of Pharmacists have adequate knowledge about
oral anticancer agents. Less than 50% apply safe handling principles adequately. Only a quarter
are conﬁdent in educating cancer patients and their caregivers about Oral Anti-Cancer Agents.
Conclusions: Pharmacists’ knowledge about Oral Anticancer agents needs to be improved. Safe han-
dling and dispensing practice of these medications should be optimized. Pharmacists’ conﬁdence
towards educating patients and their caregiver needs to be addressed. Enhancing safety of oral anti-
cancer agents should be a priority. Involving all key players, research and quality improving pro-
jects are needed to improve all aspects of the safety of oral anticancer agents.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The cancer burden is rising in many developing countries. It is
projected that cancer incidence will increase form 12.7 million
in 2008 to 22.2 million by 2030 (Bray et al., 2012). The ﬁrst oral
anti-cancer chemotherapy dates back to the 1940’s of the last
century. The therapeutic use of Nitrogen Mustard for certain
hematological malignancies was ﬁrst reported by Goodmanaceutical
Table 1 Participants’ characteristics.
Nationality Saudi 82% N= 98
Non-Saudi 18% N= 22
Gender Female 64% N= 77
Male 36% N= 43
Job description Pharmacy manager 2.6% N= 3
Clinical pharmacist 12% N= 14
Oncology pharmacist 85.4% N= 103
Years of experience Less than 3 years 37% N= 44
3–6 years 38% N= 46
7–10 years 11% N= 13
More than 10 years 14% N= 17
Degree Post-graduate degree 12% N= 14
Bachelor Degree 88% N= 106
2 S.S. Mekdad, A.D. AlSayedet al. (1984). With the increasing understanding of cancer biol-
ogy and molecular genetics a variety of Oral Anti-Cancer
Agents (OAAs) are developed targeting key cellular mecha-
nisms involved in tumour resistance to conventional therapies.
It is estimated that 25% of all targeted anticancer agents will
be oral medications and more than 400 oral agents are in the
development pipeline (Weingart et al., 2008). They are used
as single agents or in combinations to treat a variety of differ-
ent cancers. In the last decades a tremendous expansion in the
indications of OAAs has taken place in solid tumours and
hematological malignancies (Timmers et al., 2012). They
belong to different classes of medications with different modes
of action and different toxicity proﬁles. The OAAs have many
potential advantage including reducing costs by decreasing the
utilization of valuable resources such as beds, infusion areas
and health care providers time. It is also preferred by many
patients as it reduces the need and risks of invasive devices
such as central venous catheters, save time, ease of administra-
tion and more gives them a feel of control of their mediations
(Schott et al., 2011; Liu et al., 1997; O’Neill and Twelves,
2002). There are however several challenges associated with
the increasing use of OAAs pertinent to patients, caregivers,
health care providers and hospital safety systems. Patients con-
cerns include adherence, understanding complex schedules,
different side effect proﬁles, interactions with foods and other
medications and increase reliance on them to manage these
medications. The health care providers particularly pharma-
cists are facing the challenges of updating their knowledge,
reducing medications errors, safe handling, educations of
patient and their caregivers and managing side effects. The safe
handling policies and procedures for OAAs are not well devel-
oped as the parenteral anticancer agents. The practice of dis-
pensing anti-cancer agents is variable. In many countries
such as the United States and Canada, these agents are dis-
pensed and managed primarily by a community Pharmacists.
It is therefore not surprising that the published studies
addressed these challenges in all aspects of OAAs imposed
on community Pharmacists. In other countries the OAAs are
dispensed only in cancer centres or specialized hospitals with
cancer care facility and not dispensed in community
Pharmacy. We intended to address these issues facing special-
ized Oncology Pharmacists dealing routinely with OAAs in the
latter setting of specialized centres with cancer care facility.
2. Material and methods
Pharmacists involved in dispensing and handling OAAs at
three tertiary care centres with oncology services namely
King Fahad Medical city, King Saud Medical City and King
Faisal Specialist Hospital and Research Center in Riyadh,
Saudi Arabia, were included. All participants gave verbal con-
sent and participation was voluntary. The study was cross sec-
tional and extended from March 2013 to May 2014. King
Faisal Hospital had a dedicated Oncology Pharmacy and the
ﬁrst two centres had dedicated pharmacists in the main outpa-
tient pharmacy dispensing and managing the OAAs. We
designed a structured questionnaire consisting of 41 questions
testing 3 domains namely safe handling of OAAs including
Patients caregivers’ education, Knowledge of OAAs medica-
tion (usage, indications, side effects, and drug interactions)
and Pharmacists Attitudes (Conﬁdence towards dispensingPlease cite this article in press as: Mekdad, S.S., AlSayed, A.D. Towards safety of ora
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tions were used for testing the domains of OAAs knowledge.
While the answers for the safe handling domain included true,
false and choose what were applicable. All correct/incorrect
and don’t know answers are expressed in percentages. The face
value of the questionnaire was validated by 4 pharmacists and
revised by a medical oncologist. The main revision was to
include only OAAs that are standard treatment and available
for several years and in all three centres. The knowledge ques-
tions excluded newly approved medications (within the last
1 year) even if available at one of the centres. One hundred
and twenty Pharmacists answered the questionnaire.
Statistical Considerations: Descriptive statistics was used
applying SSPS version 21.3. Results
The characteristics of the participants are shown in Table 1.
Domain 1 studied the dispensing and safe handling of
OCDs with 8 questions. Although 75% acknowledge the appli-
cation of general principles of dispensing and safe handling of
OAAs, the overall correct answers, incorrect answers and
don’t know were 48%, 32% and 20% respectively. The use
of a separate counting tray was acknowledged by 93% of
pharmacist. Only one third thought protective gloves were
needed during dispensing OAAs and 43% did not believe
double checking was needed. Only 20% of pharmacist
acknowledged they provided patients and their caregivers
directions about safe handling of OAAs. The results are shown
in Table 2.
The second domain was testing the knowledge of pharma-
cists about OCDs. This included 31 questions that covered 4
areas. These four areas and the results are shown in Table 3.
The overall knowledge of pharmacists about OAAs was
poor. Pharmacists were least knowledgeable about dosing
and side effects. Only 14% answered the questions related to
side effects correctly and half of pharmacist were not sure
about the side effects associated with each medication.
The third domain was the attitudes of the pharmacist
towards OAAs, the gaps in formal education and strategies
of self-improvement. Only 26% felt somewhat conﬁdent to dis-
pense OAAs. A quarter acknowledged they received education
about OAAs in college or later in their practice. The majorityl anti-cancer agents, the need to educate our pharmacists. Saudi Pharmaceutical
Table 2 Safe handling and dispensing of anti-cancer agents.
Domain 1 Safe
handling and
dispensing of anti-
cancer agents
No of
questions
Correct
(%)
Incorrect
(%)
I
don’t
know
(%)
Dispensing and safe
handling of OCDs
8 48 32 20
Know and apply the
safety principles of
dispensing and safe
handling
1 75 18 7
Recommendation for
safe handling
1 37 33 30
Directions to patients
and care givers about
safe handling
1 20 39 40
Strategies to improve
safe handling
1 35 34 31
Safe dispensing (if the
patient unable to
swallow)
1 30 37 33
Separate counting tray
for oral chemotherapy
drugs
1 Yes No
93 7
Required double
checking
1 Yes No
57 43
Wearing Glove during
dispensing
1 Yes No
34 66
Table 3 Knowledge of pharmacists about oral anticancer
agents.
Domain 2 Number Correct
(%)
Incorrect
(%)
I don’t
know (%)
Drug knowledge 30
A-General
knowledge
11 23 35 42
B-Side eﬀects 7 14 36 50
C-Dosing
knowledge
4 18 50 32
D-Drug drug
interaction
8 22 45 33
Towards safety of oral anti-cancer agents 3agreed they would participate in further educations about
OAAs and online learning was the preferred method to
enhance knowledge. These results are shown in Table 4.
4. Discussion
OAAs are different from many medications as they pose risks
to health care providers, patients and their caregivers even
with what is considered a standard use. Special precautions
are required for safe dispensing and handling of these medica-
tions. Pharmacists are at the frontline in providing care when it
comes to oral medications and contribute to overall safety and
outcomes of these therapies. Our study highlights that there
are serious gaps in Pharmacists Knowledge about OAAs andPlease cite this article in press as: Mekdad, S.S., AlSayed, A.D. Towards safety of ora
Journal (2015), http://dx.doi.org/10.1016/j.jsps.2015.06.007there is a general lack of conﬁdence and ability to educate
patients and their caregivers. Previous published studies have
focused on community pharmacists as handling and dispensing
these medications take place primarily in the community
setting. In a study across Canada only 24% knew about the
common dosing and less than 10% felt conﬁdence in educating
patients and caregivers about OAAs (Abbott et al., 2014). In a
US study community Pharmacists fared better knowledge
about dosing principles but knowledge about side effects
remained suboptimal (45%) (O’Bryant and Crandell, 2008).
Pharmacists expressed they did not receive adequate education
at the undergraduate level 55% in our study and 59% in the
Canadian study (Abbott et al., 2014). Our study showed a
low conﬁdence towards dispensing OAAs, similarly in the
US study the conﬁdence towards dispensing was scored as
2.4/5 on a ﬁve point scoring system (O’Bryant and Crandell,
2008). These studies including ours highlight important
fact that knowledge gaps and suboptimal conﬁdence are a
concern among community and specialized pharmacists. The
pharmacists uniformly agree that they need further education
to boost their knowledge and conﬁdence towards OAAs and
to improve their ability to educate their patient and caregivers.
When it comes to safe handling practices our study high-
lights important differences between community and hospital
based practice. Safety guidelines exists in hospital practice
for OAAs evidenced by three quarters of Pharmacists
acknowledging awareness of safety principles, higher rate of
separate counting trays, use of protective clothing and double
checking. Almost 95% of US community pharmacist were not
using a separate counting tray compared to 93% using a sep-
arate tray in the specialized setting (O’Bryant and Crandell,
2008). Higher percentage have attended educational courses
70% in our study compared to 16% in the US pharmacist
study (O’Bryant and Crandell, 2008). Despite safe handling
principles and guidelines exists at facilities caring for cancer
patients our study indicates their implementations remains
suboptimal. It highlights that the interventions need to be tai-
lored according to gaps in knowledge and deﬁciencies in safe
handling and dispensing practice. Dispensing errors constitute
about 15% of the Medication related errors. Studies have
shown higher prescription of errors are related to OAAs
(Weingart et al., 2010). Studies have shown pharmacists not
applying safety standards are at risk of greater exposure to
these cytotoxic medications. Urine samples taken from
personal handling these medications have shown measurable
amounts of these medications in 40% to two thirds of the
personal who included pharmacists and other personal
handling these medications (Pethran et al., 2003; Schreiber
et al., 2003). Interventions by well-trained pharmacists have
shown to improve the outcomes of many medical conditions
(Machado et al., 2008; Chisholm-Burns et al., 2010).
Therefore improving knowledge and safe handling practices
are imperative and will undoubtedly improve patient outcomes
and safety of the providers.
There was a lack of uniform guidelines on safe handling
and dispensing OAAs in the last decade. Expanding use of
OAAs posing major concerns on safety of staff as well as
patients and caregivers had led many groups to develop
comprehensive guidelines and standards to enhance all aspects
of the safety of OAAs (Goodin et al., 2011). One of the
most comprehensive updated guidelines is the American
Society of Clinical Oncology and Oncology Nursing societyl anti-cancer agents, the need to educate our pharmacists. Saudi Pharmaceutical
Table 4 Attitude and self improvement.
Domain 3 attitude and self improvement No of
questions
Pharmacist attitude 4
Conﬁdent about dispensing oral chemotherapy 1 Conﬁdent Somewhat conﬁdent Neutral Not
conﬁdent
I don’t
know
18% 8% 16% 14% 44%
Education about oral anti-cancer agents
(Collage or postgraduate)
1 Yes No I’m not
sure
28% 55% 17%
Attend a course or continuing education 1 Yes No I don’t
know
70% 23% 7%
Preferred format of continuing education 1 Lectures written
materials
Online courses video
seminars
No
response
7% 63% 30%
Policy 
Makers
Research 
&Quality 
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care givers
Opmal 
Knowledge 
&safety of OAAS
Medical Schools & 
Learning resources
Policy &Procedures
Figure 1 Towards better safety of oral anticancer agents.
4 S.S. Mekdad, A.D. AlSayed(ASCO/ONS) guidelines for safe administration and manage-
ment of oral chemotherapy (Neuss et al., 2013). These guideli-
nes intended to involve all the stakeholders, to be
comprehensive and applicable to individuals and institutions.
In a recent multinational study by the International
Medication safety Practice (ISMP) and International
Medication safety Practice Canada (ISMPC) addressing sys-
tem based safeguards in Oncology practice identiﬁed OAAs
as a key areas that needs improvement (Greenall et al.,
2015). How to implement and adapt these guidelines and mon-
itor their applications remains a major challenge. It isPlease cite this article in press as: Mekdad, S.S., AlSayed, A.D. Towards safety of ora
Journal (2015), http://dx.doi.org/10.1016/j.jsps.2015.06.007imperative to conduct research and quality improvement pro-
grams in different practice settings involving OAAs. These
studies and quality projects will help in identifying areas of
deﬁciency in knowledge and safe handling and will aid in the
development of best assessment tools and interventions appli-
cable to the relevant practice. A proposed schema for the
potential improvement of the overall safety of the OAAs from
a pharmacists perspective is shown in Fig. 1. Our studies’
results do have limitations which include the lack of a
validated assessment tool, the inability to cover all aspects to
safety and cross comparisons to a different practice in ourl anti-cancer agents, the need to educate our pharmacists. Saudi Pharmaceutical
Towards safety of oral anti-cancer agents 5analysis. Despite these limitations we still believe limited
studies have addressed these issues and seem to reach a similar
conclusion. We provide a prospective of practice different
from the community pharmacy practice and highlight the
complexity of this subject.
5. Conclusions
The global burden of cancer is increasing. The expanding use
of OAAs is posing major concerns on safety of personal,
patients and their caregivers. The standards and guidelines
for safe handling and dispensing of these agents a not abreast
with the rapid and wide applications of these medications in
clinical practice. After collaborative initiatives more compre-
hensive guidelines addressing safe handling and dispensing of
OAAs have been developed, however their uniform implemen-
tations remains a major challenge. More studies are needed to
identify the areas for improvement relevant to each practice.
Pharmacists will remain a key player in safe handling and
dispensing these medications as well as educating patients
and caregivers. The published studies highlights major gaps
in OAAs and safe dispensing. Medical schools, policy makers,
institutions, researchers and patient advocates need to work
together to improve pharmacists’ knowledge and competency
as well as the safety of pharmacists, patients and caregivers
handling the OAAs.
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